Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today ...
Abpro successfully closed a business combination with Atlantic Coastal Acquisition Corp II, marking a significant milestone in its journey to provide advanced antibody therapies. The company raised ...
Business combination closed November 13, 2024 Raised $10 million of gross proceeds in connection with the business combination Agreements are in place with Yorkville for up to a $50 million standby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback